Every 8-K that ReShape Lifesciences, Inc. (RSLS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RSLS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RSLS filings page.
Vyome Holdings reported first quarter 2026 results and highlighted progress on its clinical pipeline and balance sheet. The company is advancing VT-1953 for malignant fungating wounds and has submitted an application to the FDA for orphan drug designation and proposals for next-stage development planning.
Cash and cash equivalents were $8.8 million as of March 31, 2026, up from $5.0 million at December 31, 2025, with total assets increasing to $10.2 million. Total stockholders’ equity rose to $8.0 million from $3.8 million, and management emphasized having no debt, no preferred stock, and no toxic financing instruments.
For the quarter ended March 31, 2026, Vyome generated revenue of $31,591, down from $198,581 a year earlier, and recorded a net loss of $985,521 versus $293,974 in the prior-year period, driven by higher operating expenses of $1.15 million. The company plans a conference call and webcast on June 3, 2026, to discuss these results.
Vyome Holdings, Inc., through subsidiary Livechain, Inc. and its unit LICH Inc., entered a Notes Purchase and Exchange Agreement to acquire senior secured convertible notes of Humanyze with aggregate principal of $5,765,000 from Remus Capital.
As consideration, Livechain will issue 211,200,844 shares of its common stock to Remus, equal to 25% of Livechain’s fully diluted common stock immediately before closing, and reserve up to 84,480,338 additional shares (10%) for compensatory grants to key and future employees. After closing, substantially all Humanyze assets and operations are expected to be transferred to the buyer entity in satisfaction of the notes.
The agreement, a related party transaction, was approved by Vyome’s audit committee and board with interested Remus-affiliated directors recusing themselves, and the outside closing date was amended to March 8, 2026. A press release states the Livechain stock issued in the transaction is valued at approximately $325,000.
Vyome Holdings, Inc. furnished an investor presentation highlighting Phase 2 results for VT-1953, a 2% topical gel for malignant fungating wounds. In a 15-patient investigator-sponsored study, VT-1953 significantly reduced malodor by Day 14 versus baseline (p=0.0020) and versus vehicle (p=0.0015), and improved patient-reported malodor impact on quality of life (p=0.0256). Patients also showed statistically significant reductions in malodor and lesion pain on visual analog scales and better composite quality-of-life scores, while exudate did not materially change. VT-1953 was well tolerated with no treatment-emergent adverse events or local reactions reported. Vyome cites a U.S. market opportunity of about $2.2 billion based on ~58,000 new patients per year and a lifetime value per patient of $55,000, and states it is capitalized to fund operations until Phase 3 interim readouts.
Vyome Holdings, Inc. furnished an investor presentation and a related product assessment report about VT-1953, its lead clinical candidate for treating symptoms of malignant fungating wounds. These materials are provided as Exhibit 99.1 under Regulation FD and are not deemed filed for liability purposes.
The company also reported that it issued a press release on January 27, 2026, summarizing key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis for VT-1953, which is attached as Exhibit 99.2. Both exhibits are incorporated by reference and include forward-looking statements about business strategy, capital needs, market potential, and future operating results.
Vyome Holdings, Inc. filed an amended Form 8-K to correct errors in previously filed pro forma financial information. The company states that Amendment No. 1 is being filed solely to replace Exhibit 99.3 with corrected Unaudited Pro Forma Condensed Combined Financial Statements, now provided as Exhibit 99.1.
No other disclosures from the original September 2, 2025 Form 8-K are modified, and the amendment does not address events occurring after that original filing date.
Vyome Holdings, Inc. reported that it has completed its previously announced merger in which Raider Lifesciences Inc., a subsidiary of the company, merged into Vyome Therapeutics, Inc., with Vyome surviving as a subsidiary. Following the merger, the registrant was renamed Vyome Holdings, Inc. and Vyome continues as Vyome Therapeutics, Inc.
The company is providing Vyome’s financial statements for the quarter ended June 30, 2025, Vyome’s Management’s Discussion and Analysis for that quarter, and unaudited pro forma condensed combined financial statements as exhibits. This information is being made available so it can be incorporated by reference into Vyome Holdings’ shelf registration statement on Form S-3.
Vyome Holdings, Inc. reported that it amended its equity distribution agreement with Maxim Group to increase the size of its at-the-market common stock offering capacity from $3,420,926 to $12,000,000, allowing shares to be sold from time to time under its existing Form S-3 shelf registration.
The company also changed its independent registered public accounting firm, dismissing Haskell & White LLP and appointing Kreit & Chiu CPA LLP for the fiscal year ending December 31, 2025, with the change approved by the audit committee and board. Vyome states there were no disagreements with Haskell on accounting or auditing matters, though Haskell’s report for the year ended December 31, 2024 included an explanatory paragraph about substantial doubt regarding Vyome’s ability to continue as a going concern and referenced material weaknesses in internal control over financial reporting.
Vyome Holdings, Inc. completed its previously announced merger in which Raider Lifesciences, a subsidiary of ReShape Lifesciences, merged into Vyome Therapeutics, Inc., making Vyome a subsidiary and prompting a corporate name change to Vyome Holdings, Inc. Common and preferred shares of Vyome were converted into ReShape common stock based on a predetermined exchange ratio, and Vyome equity awards were converted into awards over Vyome Holdings shares.
The company also closed an asset sale, transferring ReShape’s assets (excluding cash) to Biorad for $2.25 million in cash, with Biorad assuming substantially all ReShape liabilities subject to working capital adjustments. Immediately after the merger, Vyome Holdings sold 529,137 common shares at $11.02 per share and Vyome Limited sold 999 shares at $937.14 per share under a put-call arrangement.
On August 15, 2025, the company effected a 1-for-4 reverse stock split to support compliance with Nasdaq’s minimum bid price, and its shares continued trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and symbol HIND. In connection with the merger, the prior directors and key executives resigned, a new six-member board and committees were installed, Venkateswarlu Nelabhotla became Chief Executive Officer, and Robert Dickey was engaged as Interim Chief Financial Officer under a one-year, $15,000-per-month agreement.
On August 7, 2025 ReShape Lifesciences reconvened a special meeting that had been partially adjourned on July 24, 2025 to complete voting on two proposals tied to a strategic transaction. Stockholders approved the sale of substantially all of the Company’s assets to Ninjour Health International Limited, an affiliate of Biorad Medisys, Pvt. Ltd., with 1,273,715 votes for, 26,206 against and 2,305 abstentions. Shareholders also approved amendments to Article VI of the Company’s Restated Certificate of Incorporation related to the proposed merger with Vyome Therapeutics, Inc., with 1,240,191 votes for, 58,555 against and 3,480 abstentions. The approved amendments are set to take effect substantially concurrently with the Merger’s effective time.
ReShape Lifesciences (Nasdaq: RSLS) filed an 8-K (Item 8.01 – Other Events) disclosing its current status with Nasdaq listing requirements. On May 28 2025 the company received a delisting notice for failing to meet the Nasdaq Capital Market’s minimum $2.5 million stockholders’ equity requirement; equity stood at only $1.2 million as of March 31 2025.
Since the notice, ReShape raised additional capital in two transactions: (1) 593,000 common shares sold between June 3–6 2025 via its at-the-market program for $3.64 million gross proceeds, and (2) an offering completed June 9 2025 of 1,054,604 shares for $2.64 million gross proceeds. Pro forma for these raises, management states that stockholders’ equity now exceeds $2.5 million.
The company has requested a hearing before a Nasdaq Hearings Panel, which automatically stays any suspension or delisting action until the Panel issues a decision and any permitted extension period expires. Management cautions that merely surpassing the equity threshold does not guarantee continued listing; the final outcome depends on the Panel’s review.
Investors should monitor the Panel’s ruling and ReShape’s ability to sustain equity levels, as delisting would shift trading to an over-the-counter venue and could impact liquidity and valuation.